Terminated PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT03922100

Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML

A Phase I/II Study of NMS-03592088, a FLT3, KIT and CSF1R Inhibitor, in Patients With Relapsed or Refractory AML or CMML

Sponsor: Nerviano Medical Sciences

Conditions Acute Myeloid Leukemia (AML) Chronic Myelomonocytic Leukemia (CMML)

Interventions NMS-03592088

Updated 10 times since 2019 Last updated: Sep 12, 2024 Started: Apr 3, 2019 Primary completion: Aug 29, 2024 Completion: Aug 29, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Study stopped due to strategic reasons. The decision is not based on specific safety findings as the safety observed in the phase II part of the study is in line with what was reported in the phase I part.

Other terminated trials from Nerviano Medical Sciences

See all terminations from Nerviano Medical Sciences

Listed as NCT03922100, this PHASE1/PHASE2 trial focuses on Acute Myeloid Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML) and remains terminated or withdrawn. Sponsored by Nerviano Medical Sciences, it has been updated 10 times since 2019, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

10 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE1/PHASE2
Oct 2024 — Sep 2025 [monthly]

Terminated PHASE1/PHASE2

Status: Recruiting → Terminated
Sep 2024 — Oct 2024 [monthly]

Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Mar 2024 — Jul 2024 [monthly]

Recruiting PHASE1_PHASE2

Status: Unknown Status → Recruiting

▶ Show 5 earlier versions

Nov 2023 — Mar 2024 [monthly]

Unknown Status PHASE1_PHASE2

Status: Recruiting → Unknown Status
Apr 2021 — Nov 2023 [monthly]

Recruiting PHASE1_PHASE2
Jan 2021 — Apr 2021 [monthly]

Recruiting PHASE1_PHASE2
Apr 2020 — Jan 2021 [monthly]

Recruiting PHASE1_PHASE2
May 2019 — Apr 2020 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Apr 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Nerviano Medical Sciences

Data source: Nerviano Medical Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bergamo, Italy , Bologna, Italy , Brescia, Italy , Le Mans, France , Milan, Italy , Nantes, France , Pessac, France , Pierre-Bénite, France , Roma, Italy , Rozzano, Italy and 1 more location